Several days before the start of high-dose chemotherapy, another PET scan showed the persistence of the malignant lesionintheproximaltibiawithanSUVof4.6.Nofurtherfoci ofpathologicglucoseuptakeweredemonstrated.Becauseof thesefindings,afterthepatientrecoveredfromtheautologous transplant,hewentontoreceiveradiotherapytotheproximal tibiaanddistalfemuratadoseof70Gygivenin35fractions from2latero-lateralfieldswithadecreaseinsafetymargins after the dose of 50 Gy. Three months after the completion Interdigitating dendritic cell sarcoma is a very rare malignancy.Inthefewcasesreportedintheliterature,theprimary tumoroccurredintheperipherallymphnodes,spleen,lungs, bladder,duodenum,testis,orbreast [1] .Surgerywasthemain treatment modality used in the previously reported cases. Only1casestudydescribedaresponsetoABVDchemother-apy (doxorubicin, bleomycin, vinblastine, dacarbazine) [2] . Thus,therearefewdataonthechemosensitivityofinterdigitatingdendriticcellsarcoma.Somewhatmoreinformationis available on the systemic treatment of a related type of sarcomacomposedofmalignantfolliculardendriticcells.However,onlylimitedresponseshavebeenachievedinfollicular dendriticcellsarcomausingcombinationchemotherapywith regimens including CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), ABVD, DHAP (dexamethasone, cytarabine, cisplatin), EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone), ICE (ifosfamide, carboplatin, etoposide), or cisplatin/epirubicin [1, 3] . Only 1 report describes complete response after imatinib in combination with other drugs [4] . There are no published data ontheefficacyofhigh-dosechemotherapyforinterdigitating dendriticcellsarcoma.
We report on a 26-year-old male patient who was diagnosedwithinterdigitatingdendriticcellsarcomaintheproximalpartofthetibia.Thetumorinvolvedtheproximalepiphysisofthetibiaandhadinvadedtheadjacentsofttissues.The diagnosiswasmadebasedonexcisionbiopsy,andthehistologywasconfirmedby3independenthistopathologistsinthe CzechRepublicandGermany.Stagingwasperformedusing positronemissiontomography(PET)whichshowedapathologicuptakeofglucoseintheprimarylesionwithastandardizeduptakevalue(SUV)of7.71,andinanipsilateralinguinal lymphnodewithanSUVof4.28.Pelvicandabdominallymph ofradiotherapy,athirdPETscanwasdonerevealingpersistentactivityinthesiteoftheprimarytumor(SUV2.69)and reappearanceofthepathologicactivityintheinguinalregion (SUV4.09).Inguinallymphnodeswerewidelydissectedand removed,andhistologicalexaminationconfirmedadendritic cellsarcomarecurrence.Thetreatmentcontinuedwithradiotherapytotheinguinalregion.Sixmonthsaftertheinguinal surgeryandirradiation,thepatientpresentedwithapalpable lower abdominal mass, and CT scan demonstrated massive iliac lymphadenopathy which was also positive on PET scan (SUV5.9-6.73).Atpresent,thepatientisundergoingpalliativechemotherapywith2-chlorodeoxyadenosine.
Toourknowledge,thisisthefirstreportofinterdigitating dendritic cell sarcoma with primary lesions in the bone and adjacentsofttissues.Thetumorwasresistanttobothconventional lymphoma-type chemotherapy and high-dose chemotherapy.Surgeryremainstheonlyoptionwithcurativepotential in this rare type of malignancy if radical removal of the tumorisfeasible.
